Richard S Hoehn1, Koffi Wima2, Audrey E Ertel2, Alexandra Meier2, Syed A Ahmad2, Shimul A Shah2, Daniel E Abbott3,4. 1. Cincinnati Research in Outcomes and Safety in Surgery (CROSS), Department of Surgery, University of Cincinnati School of Medicine, Cincinnati, OH, USA. rshoehn@gmail.com. 2. Cincinnati Research in Outcomes and Safety in Surgery (CROSS), Department of Surgery, University of Cincinnati School of Medicine, Cincinnati, OH, USA. 3. Cincinnati Research in Outcomes and Safety in Surgery (CROSS), Department of Surgery, University of Cincinnati School of Medicine, Cincinnati, OH, USA. abbottdl@ucmail.uc.edu. 4. Division of Surgical Oncology, University of Cincinnati School of Medicine, Cincinnati, OH, USA. abbottdl@ucmail.uc.edu.
Abstract
BACKGROUND: This study aimed to analyze adjuvant therapy among patients with extrahepatic cholangiocarcinoma (EHC) at a national level. METHODS: The American College of Surgeons National Cancer Data Base was used to identify patients with resected EHC (pathologic stages 1-3) between 1998 and 2006 (n = 8741). Three groups were compared: surgery only (S, n = 5766), surgery plus adjuvant chemotherapy (AC, n = 450), and surgery plus adjuvant chemotherapy and radiation therapy (ACR, n = 1918). The study investigated how patient demographics, provider characteristics, and tumor-specific variables were associated with receipt of adjuvant therapy and overall survival. RESULTS: Patients who received adjuvant treatment were more likely to be younger (median age S, 70 years; AC, 65 years; ACR, 63 years), in the highest income quartile (>$46,000: S, 38.3 %; AC, 43.4 %; ACR, 44.7 %), and treated at a community cancer center (S, 43.0 %; AC, 50.7 %; ACR, 52.9 %) (all p < 0.001). These patients also were more likely to have positive lymph nodes (S, 34.7 %; AC, 69.6 %; ACR, 63.3 %), positive surgical margins (S, 5.9 %; AC, 7.1 %; ACR, 10.7 %), and stage 3 disease (S, 21.4 %; AC, 37.8 %; ACR, 37.9 %) (all p < 0.001). Multivariate analysis of the entire cohort showed improved survival with ACR (hazard ratio [HR] 0.82; 95 % confidence interval [CI] 0.75-0.91). The survival benefit was independent of margin status (R0: HR 0.88; 95 % CI 0.79-0.97; R1: HR 0.49; 95 % CI 0.38-0.62). CONCLUSIONS: This national analysis suggests that ACR are associated with improved survival for high-risk EHC patients, such as those with positive lymph nodes. Until randomized clinical trials are conducted, these may be the best available data to guide adjuvant therapy for resected EHC.
BACKGROUND: This study aimed to analyze adjuvant therapy among patients with extrahepatic cholangiocarcinoma (EHC) at a national level. METHODS: The American College of Surgeons National Cancer Data Base was used to identify patients with resected EHC (pathologic stages 1-3) between 1998 and 2006 (n = 8741). Three groups were compared: surgery only (S, n = 5766), surgery plus adjuvant chemotherapy (AC, n = 450), and surgery plus adjuvant chemotherapy and radiation therapy (ACR, n = 1918). The study investigated how patient demographics, provider characteristics, and tumor-specific variables were associated with receipt of adjuvant therapy and overall survival. RESULTS:Patients who received adjuvant treatment were more likely to be younger (median age S, 70 years; AC, 65 years; ACR, 63 years), in the highest income quartile (>$46,000: S, 38.3 %; AC, 43.4 %; ACR, 44.7 %), and treated at a community cancer center (S, 43.0 %; AC, 50.7 %; ACR, 52.9 %) (all p < 0.001). These patients also were more likely to have positive lymph nodes (S, 34.7 %; AC, 69.6 %; ACR, 63.3 %), positive surgical margins (S, 5.9 %; AC, 7.1 %; ACR, 10.7 %), and stage 3 disease (S, 21.4 %; AC, 37.8 %; ACR, 37.9 %) (all p < 0.001). Multivariate analysis of the entire cohort showed improved survival with ACR (hazard ratio [HR] 0.82; 95 % confidence interval [CI] 0.75-0.91). The survival benefit was independent of margin status (R0: HR 0.88; 95 % CI 0.79-0.97; R1: HR 0.49; 95 % CI 0.38-0.62). CONCLUSIONS: This national analysis suggests that ACR are associated with improved survival for high-risk EHC patients, such as those with positive lymph nodes. Until randomized clinical trials are conducted, these may be the best available data to guide adjuvant therapy for resected EHC.
Authors: Nora Schweitzer; Tim Weber; Martha M Kirstein; Mareike Fischer; Anna-Maria Kratzel; Tanja Reineke-Plaaß; Frank Lehner; Michael P Manns; Arndt Vogel Journal: J Cancer Res Clin Oncol Date: 2017-03-17 Impact factor: 4.553
Authors: Laura L Dover; Robert A Oster; Andrew M McDonald; Derek A DuBay; Thomas N Wang; Rojymon Jacob Journal: HPB (Oxford) Date: 2016-08-16 Impact factor: 3.647
Authors: Caitlin Hester; Ibrahim Nassour; Beverley Adams-Huet; Mathew Augustine; Michael A Choti; Rebecca M Minter; John C Mansour; Patricio M Polanco; Matthew R Porembka; Sam C Wang; Adam C Yopp Journal: J Gastrointest Surg Date: 2018-07-20 Impact factor: 3.452
Authors: Hoon Sik Choi; Ki Mun Kang; Bae Kwon Jeong; Hojin Jeong; Yun Hee Lee; In Bong Ha; Tae Gyu Kim; Jin Ho Song Journal: Radiat Oncol Date: 2018-05-08 Impact factor: 3.481